natgillin/translations-raw huggingface dataset:
You must agree to regular follow-up visits, ideally every month. 
• Strinjati se morate z rednimi kontrolnimi obiski zdravnika (najbolje vsak mesec).
You may not notice some changes in your mood and behaviour and so it is very important that you tell your friends and family that you are taking this medicine. 
Določenih sprememb v razpoloženju in vedenju morda ne boste sami opazili, zato je zelo pomembno,
As a minimum requirement, female patients of childbearing potential must use at least one highly effective method of contraception (i.e. a user-independent form), or two complementary user-dependent forms of contraception. 
Najmanjša zahteva za bolnice v rodni dobi je, da uporabljajo najmanj eno visoko učinkovito metodo kontracepcije (neodvisno od uporabnice), ali dve dopolnjujoči metodi kontracepcije, ki sta odvisni od uporabnice.
o [for acitretin this last bullet point should be] 
o [za acitretin se mora zadnja točka glasiti]
You must have talked about contraception (birth control) with your doctor. 
• Z zdravnikom se morate pogovoriti o kontracepciji (preprečevanju nosečnosti).
Follow-up visits 
Kontrolni obiski
4.4 Special warnings and precautions for use Teratogenic effects [TRADENAME] is a powerful human teratogen inducing a high frequency of severe and life threatening birth defects. 
Teratogeni učinki Zdravilo [ZAŠČITENO IME] je zelo teratogeno pri ljudeh in zelo pogosto povzroča hude in življenjsko ogrožajoče malformacije ploda.
for acitretin this last bullet point should be: 
• za acitretin se mora zadnja točka glasiti:
• Even if she has amenorrhea she must follow all the advice on effective contraception. 
• Bolnica mora upoštevati vsa navodila o učinkoviti kontracepciji, tudi če ima amenorejo.
It also makes a miscarriage more likely. 
Poveča tudi tveganje za splav.
Full patient information about the teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme should be given by the physician to all patients, both male and female. 
Zdravnik mora vsem bolnikom, tako ženskam kot moškim, dati podrobne informacije o tveganju za teratogenost in strogih ukrepih za preprečevanje nosečnosti, kot so opisani v programu za preprečevanje nosečnosti.
What you need to know before you take <TRADENAME> 
Kaj morate vedeti, preden boste vzeli zdravilo <ZAŠČITENO IME> Ne jemljite zdravila <ZAŠČITENO IME>
Women who are pregnant must not take <TRADENAME> 
Program za preprečevanje nosečnosti Bolnice, ki so noseče, ne smejo jemati zdravila <ZAŠČITENO IME>
Mental problems 
Duševne motnje
The following boxed warning should be included in the PL for the oral retinoids acitretin, alitretinoin and isotretinoin, under the invented name: 
V navodilo za uporabo je treba vključiti sledeče opozorilo v okvirju za retinoide acitretin, alitretinoin in izotretinoin, ki se jemljejo peroralno, pod zaščitenim imenom:
Very rare effects (may affect up to 1 in every 10,000 people) 
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov)
• Negative pregnancy test results have been obtained before, during and 1 month after the end of treatment. 
• Ima negativen test nosečnosti pred, med in 1 mesec po zaključku zdravljenja.
Section 4.4 Special warnings and precautions for use Psychiatric disorders 
Poglavje 4.4 Posebna opozorila in previdnostni ukrepi
You must not take <TRADENAME> if you are pregnant or if you think you might be pregnant. 
Ne uporabljajte, če ste noseči ali če mislite, da ste noseči.
Ideally, pregnancy testing, issuing a prescription and dispensing of [TRADENAME] should occur on the same day. 
Najbolje je, da se test nosečnosti izvede na isti dan, kot se predpiše recept in izda zdravilo [ZAŠČITENO IME].
Your doctor may tell you to stop taking <TRADENAME>. 
Zdravnik bo morda prekinil vaše zdravljenje z zdravilom <ZAŠČITENO IME>.
Patients should not donate blood during therapy and for 1 month [3 years for acitretin] following discontinuation of [INN] because of the potential risk to the foetus of a pregnant transfusion recipient. 
Med zdravljenjem in en mesec [3 leta za acitretin] po končanem zdravljenju z [mednarodno nelastniško ime] bolniki ne smejo darovati krvi zaradi možnega škodljivega vpliva na plod nosečnice, ki prejme transfuzijo krvi.
The doctor may send you to a specialist for contraception advice. 
Zdravnik vam bo dal informacije o preprečevanju nosečnosti in vas morda napotil k specialistu po nasvet glede kontracepcije.
[TRADENAME] is strictly contraindicated in: - Pregnant women - Women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met Pregnancy Prevention Programme This medicinal product is TERATOGENIC [INN] is contraindicated in women of childbearing potential unless all of the following conditions of the Pregnancy Prevention Programme are met: 
- nosečnicah - ženskah v rodni dobi, razen če so izpolnjeni vsi pogoji programa za preprečevanje nosečnosti.
Women should undergo pregnancy test periodically with 1-3 monthly intervals for a period of 3 years after stopping treatment. 
Ženske morajo po prenehanju zdravljenja nosečnostne teste izvajati v presledkih od 1 do 3 mesecev v obdobju 3 let po uporabi zadnjega odmerka.
The following adverse reaction(s) should be included: 
Dodati je potrebno sledeče neželene učinke:
Particulars to appear on the outer packaging 
Podatki na zunanji ovojnini Škatla
• She understands the need and accepts to undergo regular pregnancy testing before, ideally monthly during treatment and 1 month after stopping treatment. 
• Bolnica razume potrebo in sprejme redna testiranja nosečnosti pred, mesečno med zdravljenjem in 1 mesec po zaključku zdravljenja.
• She understands the need and accepts to undergo regular pregnancy testing before, ideally monthly during treatment and periodically with 1-3 monthly intervals for a period of 3 years after stopping treatment. 
• Bolnica razume potrebo in sprejme redna testiranja nosečnosti pred, mesečno med zdravljenjem in periodično v 1 do 3 mesečnih intervalih še 3 leta po zaključku zdravljenja.
Signs of this include sad or altered mood, anxiety, feelings of emotional discomfort 
Znaki vključujejo slabo voljo ali spremembe razpoloženja, tesnobo, siljenje na jok.
Male patients 
Navodilo za bolnika
• She understands and accepts the need for effective contraception, without interruption, 1 month before starting treatment, throughout the entire duration of treatment and for 1 month [3 years for acitretin] after the end of treatment. 
• Bolnica razume in sprejema pogoje za uporabo zanesljive neprekinjene kontracepcijske zaščite 1 mesec pred začetkom zdravljenja, med zdravljenjem in še 1 mesec [3 leta za acitretin] po zaključku zdravljenja.
You should never give this medicinal product to another person. 
Tega zdravila ne smete deliti z nikomer.
You must use contraception for a month before taking <TRADENAME>, during treatment and for a month afterwards [for acitretin should be during 3 years] 
IME>, med zdravljenjem in še en mesec po njem [za acitretin mora biti navedeno 3 leta].
Also, if you become pregnant within one month [3 years for acitretin] after you stop taking <TRADENAME>, you should contact your doctor. 
Tudi če zanosite v enem mesecu [v 3 letih za acitretin] po prenehanju jemanja zdravila <ZAŠČITENO
{Active substance(s)} 
leta za acitretin].
DO NOT use <TRADENAME> if you are pregnant or thinking of becoming pregnant. 
Ne uporabljajte zdravila <ZAŠČITENO IME>, če ste noseči ali načrtujete nosečnost.
[for acitretin this last paragraph should be] 
[za acitretin se mora zadnji odstavek glasiti]
CAN SERIOUSLY HARM AN UNBORN BABY Women must use effective contraception Do not use if you are pregnant or think you may be pregnant 
LAHKO RESNO ŠKODUJE NEROJENEMU OTROKU Ženske morajo uporabljati zanesljivo kontracepcijo.
A contraindication should be added as follows: Section 4.3 Contraindications: 
Opozorilo glede psihiatričnih motenj je potrebno spremeniti kot sledi: Poglavje 4.4 Posebna opozorila in previdnostni ukrepi
• Individual circumstances should be evaluated in each case, when choosing the contraception method, involving the patient in the discussion, to guarantee her engagement and compliance with the chosen measures. 
• Pri izbiri kontracepcijske metode je posamezne okoliščine treba oceniti za vsak primer posebej,
Annex III Amendments to relevant sections of the product information 
Spremembe relevantnih poglavij povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo
You must not take <TRADENAME> if you could get pregnant during treatment. 
• Zdravila < ZAŠČITENO IME > ne smete jemati, če obstaja možnost, da med zdravljenjem zanosite.
The available data suggest that the level of maternal exposure from the semen of the patients receiving [TRADENAME], is not of a sufficient magnitude to be associated with the teratogenic effects of [TRADENAME]. 
Moški bolniki Podatki, ki so na razpolago, kažejo, da maternalna izpostavljenost semenčicam bolnikov, ki prejemajo
This is because your mood may be affected while taking <TRADENAME>. 
Med jemanjem zdravila <ZAŠČITENO IME> se namreč lahko vaše razpoloženje spremeni.
• Negative pregnancy test results have been obtained before, during and periodically with 1-3 monthly intervals for a period of 3 years after stopping treatment. 
• Ima negativen test nosečnosti pred, med zdravljenjem in v presledkih od 1 do 3 mesecev v obdobju 3 let po uporabi zadnjega odmerka.
The levels of oral retinoid in the semen of men taking <TRADENAME> are too low to harm their partners' unborn baby. 
je prenizka, da bi škodovala nerojenemu otroku vaše partnerke.
− If you are pregnant 
• Če ste noseči ali dojite.
You must not take <TRADENAME> if you are breastfeeding. 
• Zdravila <ZAŠČITENO IME> ne smete jemati, če dojite.
At least one highly effective method of contraception (i.e. a user-independent form) or two complementary user-dependent forms of contraception should be used. 
(obliko, neodvisno od uporabnice) ali dve dopolnjujoči obliki kontracepcije, ki sta odvisni od uporabnice.
A boxed warning should be added to the outer packaging for the oral retinoids acitretin, alitretinoin and isotretinoin as follows: 
Na zunanjo ovojnino za retinoide acitretin, alitretinoin in izotretinoin, ki se jemljejo peroralno, je potrebno dodati opozorilo v okvirju, kot sledi:
[for acitretin this last bullet point should be] 
• [za acitretin se mora zadnja točka glasiti]
You should not donate blood during treatment with this medicine and for 1 month [3 years for acitretin] after stopping <TRADENAME> because an unborn baby could be harmed if a pregnant patient receives your blood. 
Med zdravljenjem s tem zdravilom in mesec dni [3 leta za acitretin] po koncu zdravljenja z zdravilom <ZAŠČITENO IME> ne smete darovati krvi kot krvodajalec.
You must not get pregnant for one month after stopping this treatment because some medicine may still be left in your body. 
• Po zaključku zdravljenja še en mesec ne smete zanositi, ker je lahko zdravilo še vedno prisotno v vašem telesu.
You must not get pregnant for 3 years after stopping this treatment because some medicine may still be left in your body. 
• Po zaključku zdravljenja še 3 leta ne smete zanositi, ker je lahko zdravilo še vedno prisotno v vašem telesu.
Prior to starting therapy 
Pred pričetkom zdravljenja
• The patient complies with the conditions for pregnancy prevention as listed above, including confirmation that she has an adequate level of understanding. 
• bolnica razume in izpolnjuje zgoraj navedene pogoje za preprečevanje nosečnosti.
For all topical retinoids containing adapalene, alitretinoin, isotretinoin, tretinoin and tazarotene, the existing product information shall be amended (insertion, replacement or deletion of the text, as appropriate) to reflect the agreed wording as provided below. 
Za vse retinoide za lokalno uporabo, ki vsebujejo adapalen, alitretinoin, izotretinoin, tretinoin in tazaroten, je treba obstoječe informacije o zdravilu (z vstavljanjem, nadomeščanjem ali črtanjem besedila, kot je ustrezno) spremeniti tako, da bodo odražale dogovorjeno besedilo, navedeno spodaj.
Depression, depression aggravated, anxiety, and mood alterations have been reported in patients treated with systemic retinoids, including <INN>. 
Psihiatrične motnje Pri bolnikih, zdravljenih s sistemskimi retinoidi, vključno z <mednarodno nelastniško ime>, so poročali o depresiji, poslabšanju depresije, anksioznosti in spremembah razpoloženja.
You must not get pregnant during treatment or for a month afterwards because some medicine may still be left in your body. 
• Med zdravljenjem in še en mesec po koncu zdravljenja ne smete zanositi, ker je zdravilo še vedno lahko prisotno v vašem telesu.
- Pregnancy (see section 4.6) - Women planning a pregnancy 
Poglavje 4.3 Kontraindikacije: − nosečnost (glejte poglavje 4.6)
For all oral retinoids containing acitretin, tretinoin and bexarotene, the existing product information shall be amended (insertion, replacement or deletion of the text, as appropriate) to reflect the agreed wording as provided below. 
Za vse retinoide, ki se uporabljajo peroralno in vsebujejo acitretin, tretinoin in beksaroten, je treba obstoječe informacije o zdravilu (z vstavljanjem, nadomeščanjem ali črtanjem besedila, kot je ustrezno) spremeniti tako, da bodo odražale dogovorjeno besedilo, navedeno spodaj.
You must not get pregnant during treatment or for 3 years afterwards because some medicine may still be left in your body. 
• Med zdravljenjm in še 3 leta po zaključku zdravljenja ne smete zanositi, ker je lahko zdravilo še vedno prisotno v vašem telesu.
For all oral retinoids products containing alitretinoin and isotretinoin, the existing product information shall be amended (insertion, replacement or deletion of the text, as appropriate) to reflect the agreed wording as provided below. 
Za vse retinoide, ki se uporabljajo peroralno in vsebujejo alitretinoin in izotretinoin, je treba obstoječe informacije o zdravilu (z vstavljanjem, nadomeščanjem ali črtanjem besedila, kot je ustrezno) spremeniti tako, da bodo odražale dogovorjeno besedilo, navedeno spodaj.
For all oral retinoids containing acitretin, alitretinoin and isotretinoin, the existing product information shall be amended (insertion, replacement or deletion of the text, as appropriate) to reflect the agreed wording as provided below 
Za retinoidna zdravila, ki se jemljejo peroralno in vsebujejo acitretin, alitretinoin in izotretinoin, je treba obstoječe informacije o zdravilu (z vstavljanjem, nadomeščanjem ali črtanjem besedila, kot je ustrezno) spremeniti tako, da bodo odražale dogovorjeno besedilo, navedeno spodaj.
The European Commission granted a marketing authorisation valid throughout the European Union for Levemir on 1 June 2004. 
Evropska komisija je dovoljenje za promet z zdravilom Levemir, veljavno po vsej Evropski uniji, izdala 1. junija 2004.
What measures are being taken to ensure the safe and effective use of Levemir? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Levemir?
Levemir can be given at any time of day, provided that it is the same time each day. 
Zdravilo Levemir se lahko daje kadar koli čez dan, vendar vsak dan ob istem času.
The change means that it is absorbed more slowly by the body, and takes longer to reach its target in the body. 
Razlika se odraža v tem, da ga telo počasneje absorbira, zaradi česar traja dlje, da v telesu doseže svoj cilj.
The full EPAR for Levemir can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Levemir je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Levemir has not been studied in children below one year of age. 
Zdravila Levemir niso proučevali pri otrocih, mlajših od enega leta.
For more information about treatment with Levemir, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Levemir preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Levemir, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
A risk management plan has been developed to ensure that Levemir is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Levemir je bil pripravljen načrt obvladovanja tveganj.
The CHMP decided that Levemir's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Levemir večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
What benefit has Levemir shown during the studies? 
Kakšne koristi je zdravilo Levemir izkazalo med študijami?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levemir. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Levemir has been studied in 1,575 adult patients with type 1 diabetes (when the pancreas cannot produce insulin) and over 2,500 adult patients with type 2 diabetes (when the body is unable to use insulin effectively). 
Zdravilo Levemir so proučili pri 1 575 odraslih bolnikih s sladkorno boleznijo tipa 1 (pri kateri trebušna slinavka ne more tvoriti insulina) in pri več kot 2 500 bolnikih s sladkorno boleznijo tipa 2 (pri kateri telo ne more učinkovito izrabiti insulina).
Levemir is given as an injection under the skin in the abdominal (tummy) wall, the thigh, the upper arm, the shoulder or the buttock. 
Zdravilo Levemir se injicira v podkožje trebušne stene (trebuha), stegna, nadlakti, ramena ali zadnjice.
This document is a summary of the European public assessment report (EPAR) for Levemir. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Levemir.
In four of the six studies in type 2 diabetes, patients also received one or two antidiabetes medicines taken by mouth. 
V štirih od šestih študij sladkorne bolezni tipa 2 so bolniki prejemali tudi eno ali dve peroralni zdravili za zdravljenje sladkorne bolezni.
What is the risk associated with Levemir? 
Kakšna tveganja so povezana z zdravilom Levemir?
Insulin detemir is very slightly different from human insulin. 
Insulin detemir se zelo malo razlikuje od človeškega insulina.
• alone as basal insulin 
• samostojno kot bazalni insulin;
The most common side effect with Levemir (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels). 
Najpogostejši neželeni učinek zdravila Levemir (opažen pri več kot 1 bolniku od 10) je hipoglikemija (nizka raven glukoze v krvi).
This means that Levemir has a long duration of action. 
To pomeni, da ima zdravilo Levemir dolgotrajni učinek.
Why has Levemir been approved? 
Zakaj je bilo zdravilo Levemir odobreno?
The dose of Levemir should be adjusted according to the individual patient's blood glucose (sugar) levels, which should be regularly tested to find the lowest effective dose. 
Njegov odmerek je treba prilagoditi glede na raven glukoze (sladkorja) v krvi vsakega posameznega bolnika, ki jo je treba redno preverjati, da se določi najnižji učinkoviti odmerek.
The effects of Levemir have also been studied in combination with metformin and liraglutide (a GLP-1 receptor agonist). 
Učinke zdravila Levemir so proučevali tudi v kombinaciji z metforminom in liraglutidom (agonist receptorjev glukagonu podobnega peptida 1 (GLP-1)).
All of the studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled. 
V vseh študijah so merili koncentracijo snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je glukoza v krvi uravnana.
In one study, 323 patients with type 2 diabetes whose blood glucose levels were not well controlled with metformin and liraglutide either received Levemir in addition to their treatment or continued on metformin and liraglutide alone. 
V eni študiji je 323 bolnikov s sladkorno boleznijo tipa 2, katerih ravni glukoze v krvi niso bile zadostno nadzorovane z metforminom in liraglutidom, prejemali zdravilo Levemir bodisi kot dodatek obstoječemu zdravljenju ali pa so nadaljevali zdravljenje samo z metforminom in liraglutidom.
• in combination with a type of diabetes medicines called GLP-1 receptor agonists that are given by injection. 
• v kombinaciji z vrsto zdravil proti sladkorni bolezni, imenovano agonist receptorjev glukagonu podobnega peptida 1 (GLP-1), ki se dajejo z injiciranjem.
Other information about Levemir: 
Druge informacije o zdravilu Levemir
Patients using Levemir in combination with liraglutide and metformin achieved a decrease of 0.5% in Hb1Ac compared with no decrease in patients using liraglutide and metformin alone. 
Pri bolnikih, ki so uporabljali zdravilo Levemir v kombinaciji z liraglutidom in metforminom, se je raven HbA1c znižala za 0,5 % v primerjavi z bolniki, ki so uporabljali samo liraglutid in metformin, pri katerih ni prišlo do znižanja.
For the full list of all side effects and restrictions with Levemir, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Levemir glejte navodilo za uporabo.
The studies compared Levemir with human insulin NPH (an intermediate-acting insulin) or insulin glargine (a long-acting insulin) given once or twice a day. 
V študijah so primerjali zdravilo Levemir s človeškim insulinom NPH (srednjedolgodelujočim insulinom) ali insulinom glarginom (dolgodelujočim insulinom), ki se daje dvakrat na dan.
Levemir has also been studied in two main studies involving 695 children and adolescents with diabetes aged 2-17 years in combination with insulin aspart and comparing it to insulin NPH. 
Zdravilo Levemir v kombinaciji z insulinom aspartom so proučevali tudi v dveh glavnih študijah, v kateri je bilo vključenih 695 otrok in mladostnikov s sladkorno boleznijo, starih od dve do 17 let, in v okviru katerih so ga primerjali z insulinom NPH.
Levemir doses might need to be adjusted when given with some other medicines that may have an effect on blood glucose levels. 
Odmerke zdravila Levemir bo morda treba prilagoditi, če se jemlje sočasno z nekaterimi drugimi zdravili, ki vplivajo na raven glukoze v krvi.
It is available in cartridges and in pre-filled pens. 
Na voljo je v vložkih in napolnjenih injekcijskih peresih.
The studies showed that Levemir controls blood glucose levels in a similar manner to insulin NPH, with less risk of low blood glucose levels during the night and no associated weight gain. 
Študije so pokazale, da zdravilo Levemir podobno uravnava ravni glukoze v krvi kot insulin NPH, vendar z manj tveganja za znižanje ravni glukoze v krvi ponoči in brez hkratnega povečevanja telesne mase.
Injections of fast-acting insulin were also used at mealtimes. 
Med jedjo so uporabili tudi injekcije hitrodelujočega insulina.
Levemir is a long-acting insulin. 
Zdravilo Levemir je insulin z dolgotrajnim delovanjem.
Levemir is a replacement insulin that is very similar to the insulin made by the body. 
Zdravilo Levemir je nadomestni insulin, ki je zelo podoben tistemu, ki ga proizvaja telo.
• in combination with injections of a short- or rapid-acting insulin at mealtimes 
• v kombinaciji z injekcijami počasi- ali hitrodelujočega insulina med jedjo;
• in combination with diabetes medicines taken by mouth 
• v kombinaciji z zdravili proti sladkorni bolezni, ki se zaužijejo peroralno;